239 related articles for article (PubMed ID: 19039757)
1. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
Koziński M; Bielis L; Wiśniewska-Szmyt J; Sukiennik A; Grabczewska Z; Swiatkiewicz I; Ziołkowski M; Rość D; Kubica J
Cardiol J; 2008; 15(6):530-6. PubMed ID: 19039757
[TBL] [Abstract][Full Text] [Related]
2. Diurnal variation in platelet inhibition by clopidogrel.
Kozinski M; Bielis L; Wisniewska-Szmyt J; Boinska J; Stolarek W; Marciniak A; Kubica A; Grabczewska Z; Navarese EP; Andreotti F; Siller-Matula JM; Rosc D; Kubica J
Platelets; 2011; 22(8):579-87. PubMed ID: 21627410
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
4. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
[TBL] [Abstract][Full Text] [Related]
5. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
[TBL] [Abstract][Full Text] [Related]
6. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Kuliczkowski W; Greif M; Gąsior M; Kaczmarski J; Pres D; Poloński L
Kardiol Pol; 2011; 69(6):531-7. PubMed ID: 21678284
[TBL] [Abstract][Full Text] [Related]
7. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction.
Zalewski J; Durak M; Lech P; Gajos G; Undas A; Nessler J; Rosławiecka A; Zmudka K
Kardiol Pol; 2012; 70(7):677-84. PubMed ID: 22825940
[TBL] [Abstract][Full Text] [Related]
10. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
11. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
12. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
Mesquita A; Baptista J; Palos J; Seabra-Gomes R
J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
Matetzky S; Fefer P; Shenkman B; Varon D; Savion N; Hod H
Am J Cardiol; 2008 Sep; 102(5):524-9. PubMed ID: 18721506
[TBL] [Abstract][Full Text] [Related]
14. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
Campo G; Valgimigli M; Gemmati D; Percoco G; Tognazzo S; Cicchitelli G; Catozzi L; Malagutti P; Anselmi M; Vassanelli C; Scapoli G; Ferrari R
J Am Coll Cardiol; 2006 Dec; 48(11):2178-85. PubMed ID: 17161242
[TBL] [Abstract][Full Text] [Related]
15. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
16. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS
Platelets; 2010; 21(3):183-90. PubMed ID: 20201634
[TBL] [Abstract][Full Text] [Related]
19. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
[TBL] [Abstract][Full Text] [Related]
20. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Estévez-Loureiro R; Salgado-Fernández J; Marzoa-Rivas R; Barge-Caballero E; Pérez-Pérez A; Noriega-Concepción V; Calviño-Santos R; Vázquez-Rodríguez JM; Vázquez-González N; Castro-Beiras A; Kaski JC
Thromb Res; 2009 Nov; 124(5):536-40. PubMed ID: 19467699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
